Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 12543 | 4.78 |
09:34 ET | 1463 | 4.8 |
09:36 ET | 5002 | 4.81 |
09:38 ET | 4066 | 4.85 |
09:39 ET | 14550 | 4.79 |
09:41 ET | 2599 | 4.84 |
09:43 ET | 16536 | 4.83 |
09:45 ET | 2512 | 4.87 |
09:48 ET | 4927 | 4.84 |
09:50 ET | 3659 | 4.83 |
09:52 ET | 2485 | 4.8605 |
09:54 ET | 2450 | 4.8801 |
09:56 ET | 14350 | 4.92 |
09:57 ET | 10535 | 4.935 |
09:59 ET | 12598 | 4.99 |
10:01 ET | 16092 | 4.94 |
10:03 ET | 16931 | 4.97 |
10:06 ET | 7175 | 4.93 |
10:08 ET | 1548 | 4.925 |
10:10 ET | 3900 | 4.9393 |
10:12 ET | 6996 | 4.94 |
10:14 ET | 1217 | 4.95 |
10:15 ET | 12806 | 4.95 |
10:17 ET | 25306 | 4.865 |
10:19 ET | 26853 | 4.85 |
10:21 ET | 11216 | 4.8 |
10:24 ET | 7811 | 4.785 |
10:26 ET | 4023 | 4.77 |
10:28 ET | 21538 | 4.745 |
10:30 ET | 18020 | 4.74 |
10:32 ET | 2213 | 4.746 |
10:33 ET | 12498 | 4.79 |
10:35 ET | 2598 | 4.82 |
10:37 ET | 13950 | 4.81 |
10:39 ET | 3691 | 4.79 |
10:42 ET | 1736 | 4.81 |
10:44 ET | 2290 | 4.785 |
10:46 ET | 1855 | 4.815 |
10:48 ET | 800 | 4.8 |
10:50 ET | 954 | 4.805 |
10:51 ET | 1964 | 4.82 |
10:53 ET | 9767 | 4.74 |
10:55 ET | 1307 | 4.75 |
10:57 ET | 1670 | 4.755 |
11:00 ET | 5864 | 4.715 |
11:02 ET | 11950 | 4.74 |
11:04 ET | 11258 | 4.75 |
11:06 ET | 1300 | 4.7402 |
11:08 ET | 1000 | 4.75 |
11:09 ET | 4431 | 4.73 |
11:11 ET | 2303 | 4.725 |
11:13 ET | 2521 | 4.75 |
11:15 ET | 700 | 4.75 |
11:18 ET | 2057 | 4.73 |
11:20 ET | 936 | 4.725 |
11:22 ET | 1200 | 4.725 |
11:24 ET | 2566 | 4.73 |
11:26 ET | 5899 | 4.7395 |
11:27 ET | 19469 | 4.7495 |
11:29 ET | 5465 | 4.77 |
11:31 ET | 1155 | 4.78 |
11:33 ET | 3600 | 4.7599 |
11:36 ET | 1156 | 4.765 |
11:38 ET | 9933 | 4.735 |
11:40 ET | 900 | 4.735 |
11:42 ET | 1024 | 4.74 |
11:44 ET | 4354 | 4.76 |
11:45 ET | 8692 | 4.765 |
11:47 ET | 1700 | 4.75 |
11:49 ET | 858 | 4.745 |
11:51 ET | 500 | 4.75 |
11:54 ET | 500 | 4.75 |
11:56 ET | 2254 | 4.735 |
11:58 ET | 1200 | 4.73 |
12:00 ET | 200 | 4.74 |
12:02 ET | 2494 | 4.73 |
12:03 ET | 2600 | 4.72 |
12:05 ET | 3605 | 4.71 |
12:07 ET | 6482 | 4.71 |
12:09 ET | 1238 | 4.715 |
12:14 ET | 2194 | 4.715 |
12:18 ET | 100 | 4.715 |
12:20 ET | 300 | 4.715 |
12:21 ET | 6632 | 4.7 |
12:23 ET | 2208 | 4.705 |
12:25 ET | 925 | 4.705 |
12:27 ET | 100 | 4.705 |
12:30 ET | 1978 | 4.71 |
12:32 ET | 29926 | 4.655 |
12:34 ET | 5649 | 4.6711 |
12:36 ET | 4673 | 4.65 |
12:39 ET | 3135 | 4.645 |
12:41 ET | 4755 | 4.625 |
12:43 ET | 2207 | 4.625 |
12:45 ET | 1737 | 4.615 |
12:48 ET | 7659 | 4.64 |
12:50 ET | 4094 | 4.65 |
12:52 ET | 2365 | 4.63 |
12:54 ET | 5714 | 4.62 |
12:56 ET | 2150 | 4.61 |
12:57 ET | 5439 | 4.64 |
12:59 ET | 4532 | 4.615 |
01:01 ET | 1724 | 4.625 |
01:03 ET | 3732 | 4.635 |
01:06 ET | 1600 | 4.61 |
01:08 ET | 2100 | 4.62 |
01:10 ET | 13179 | 4.6301 |
01:12 ET | 5127 | 4.61 |
01:14 ET | 4675 | 4.6101 |
01:15 ET | 3257 | 4.62 |
01:17 ET | 1227 | 4.62 |
01:19 ET | 200 | 4.6158 |
01:21 ET | 900 | 4.62 |
01:24 ET | 12362 | 4.655 |
01:26 ET | 4457 | 4.67 |
01:28 ET | 2300 | 4.67 |
01:30 ET | 2227 | 4.67 |
01:32 ET | 500 | 4.68 |
01:33 ET | 509 | 4.69 |
01:35 ET | 300 | 4.69 |
01:37 ET | 1400 | 4.71 |
01:39 ET | 10136 | 4.69 |
01:42 ET | 1087 | 4.685 |
01:44 ET | 600 | 4.685 |
01:46 ET | 1534 | 4.71 |
01:48 ET | 500 | 4.72 |
01:50 ET | 200 | 4.72 |
01:51 ET | 800 | 4.72 |
01:53 ET | 5705 | 4.74 |
01:55 ET | 13111 | 4.76 |
01:57 ET | 1312 | 4.745 |
02:02 ET | 1740 | 4.735 |
02:04 ET | 200 | 4.74 |
02:06 ET | 600 | 4.735 |
02:08 ET | 1000 | 4.74 |
02:09 ET | 5754 | 4.74 |
02:11 ET | 400 | 4.75 |
02:13 ET | 1400 | 4.75 |
02:15 ET | 3480 | 4.73 |
02:18 ET | 425 | 4.715 |
02:20 ET | 500 | 4.72 |
02:22 ET | 800 | 4.71 |
02:24 ET | 400 | 4.705 |
02:27 ET | 1526 | 4.7175 |
02:29 ET | 3414 | 4.71 |
02:31 ET | 1888 | 4.72 |
02:33 ET | 4377 | 4.695 |
02:36 ET | 500 | 4.7 |
02:38 ET | 581 | 4.69 |
02:40 ET | 2715 | 4.685 |
02:42 ET | 956 | 4.69 |
02:44 ET | 815 | 4.69 |
02:45 ET | 600 | 4.69 |
02:47 ET | 300 | 4.69 |
02:49 ET | 300 | 4.68 |
02:51 ET | 905 | 4.685 |
02:54 ET | 3919 | 4.7 |
02:56 ET | 500 | 4.7 |
02:58 ET | 14349 | 4.65 |
03:00 ET | 300 | 4.66 |
03:02 ET | 600 | 4.65 |
03:03 ET | 1250 | 4.657 |
03:05 ET | 2575 | 4.665 |
03:07 ET | 2300 | 4.665 |
03:09 ET | 700 | 4.665 |
03:12 ET | 1733 | 4.66 |
03:14 ET | 100 | 4.655 |
03:18 ET | 3328 | 4.645 |
03:20 ET | 1394 | 4.645 |
03:21 ET | 3566 | 4.66 |
03:23 ET | 3241 | 4.66 |
03:25 ET | 1513 | 4.66 |
03:27 ET | 1425 | 4.665 |
03:30 ET | 2362 | 4.675 |
03:32 ET | 2691 | 4.68 |
03:34 ET | 700 | 4.685 |
03:36 ET | 4412 | 4.695 |
03:38 ET | 2567 | 4.7 |
03:39 ET | 400 | 4.7 |
03:41 ET | 3188 | 4.685 |
03:43 ET | 15843 | 4.675 |
03:45 ET | 17841 | 4.655 |
03:48 ET | 1100 | 4.655 |
03:50 ET | 8949 | 4.66 |
03:52 ET | 60377 | 4.705 |
03:54 ET | 18385 | 4.7 |
03:56 ET | 40045 | 4.69 |
03:57 ET | 29598 | 4.66 |
03:59 ET | 78790 | 4.65 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.3B | -3.0x | --- |
Biohaven Ltd | 3.1B | -6.3x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Iovance Biotherapeutics Inc | 3.1B | -6.0x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -14.9x | --- |
Apogee Therapeutics Inc | 3.0B | -30.6x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.26 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.